Zacks.com on MSN4h
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...
Amicus expects to surpass $1B in total sales in 2028
Amicus (FOLD) is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The ...